Alzheimer's disease: Cost cuts call for novel drugs development and national strategy

Ceska a Slovenska Farmacie

Volumn 64, Issue , 2015, Pages 25-30

  Marešová, Petra ^a   Klímová, Blanka ^a   Kuča, Kamil ^a  

^a UNIVERSITY OF HRADEC KRALOVE   (Czech Republic)

Author keywords

Alzheimer's disease; Costs; Strategic plan; Treatment

Indexed keywords

NOOTROPIC AGENT;

AGING; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CZECH REPUBLIC; DRUG COST; DRUG RESEARCH; EARLY DIAGNOSIS; HEALTH CARE COST; HUMAN; INSTITUTIONALIZATION; QUALITY OF LIFE; DRUG DEVELOPMENT;

ALZHEIMER DISEASE; CZECH REPUBLIC; DRUG DISCOVERY; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS;

EID: 84937426325     PISSN: 12107816     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. MPSV. Preparing for aging. Portal of the Ministry of Labour and Social Affairs 2008; Available from http://www.mpsv. cz/cs/2856 (cited 2014 June 23).
2. European Commission. The impact of ageing on public expenditure: projections for the EU25 Member States on pensions, health care, long-term care, education and unemployment transfers. 2006. The report of the Economic Policy Committee and the Directorate General. 2006. http://www.worldbank.org/en/news/feature/2013/01/17/the-eu-11-in-an-aging-europe (cited 2015 March 23).
3. Eurostat: Population structure and ageing. 2014. http://ec.europa.eu/eurostat/statistics-explained/index.php/Population-structure-and-ageing (cited 2015 March 23).
4. Association of Independent Unions of the Czech Republic. Materials regular meeting of the 96th Plenary Session of 23rd February 2012. http://www.asocr.cz/cz/portal/dokumenty/tripartita/materialy-na-radne-zasedani-96-plenarni-schuze-rhsd-cr-dne-23-unora-2012-526.htm. (cited 2014 June 23)
5. Ministry of Health of Czech Republic. Health 2020: Framework summary measures [online] 2013. file:///C:/Users/Maresova/Downloads/WHO-Zdrav%C3%AD-2020-P%C5%99eklad-CZ.p df (cited 2014 June 23)
6. Mega M. S., Cummings J. L., Fiorello T., Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46(1), 130-135.
7. Opara J. A. Activities of daily living and quality of life in Alzheimer disease. J. Med. Life 2012;5(2), 162-167.
8. Maresova P., Mohelska H., Kuca K. Cooperation Policy of Rare Diseases in the European Union. 5th ICEEPSY International Conference on Education & Educational Psychology 2015;171, 1302-1308.
9. Maresova P., Tomaskova H., Kuca K. The Use of Simulation Modelling in the Analysis of the Economic Aspects of Diseases in Old Age. EBES Conference Eurasia Business and Economics 2014; In press.
10. Castro D., Dillon C., Machnicki G., Allegri R. The economic cost of Alzheimer's disease: family or public-health burden? Dement. Neuropsychol. 2010;4, 262-267.
11. Gervès C., Chauvin P., Bellanger M. M., Meidani A. Evaluation of full costs of care for patients with Alzheimer's disease in France: The predominant role of informal care. Health Policy 2014;116, 114-122.
12. Schwarzkopf L., Menn P., Kunz S., Holle R., Lauterberg J., Marx P., Mehlig H., Wunder S., Leidl R., Donath C., Graessel E. Costs of care for dementia patients in community setting: An analysis for mild and moderate disease stage. Value in Health 2011;14, 827-835.
13. Getsios D., Blume S., Khajak J. I., Maclaine G. and Hernández L. An economic evaluation of early assessment for Alzheimer's disease in the united kingdom. Alzheimer's 2012;8, 22-30.
14. Wang G, Cheng Q, Zhang S, et al. Economic impact of dementia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai, China. J. Alzheimer Dis. 2008;15, 109-115.
15. Mangialasche F., et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010;9, 702-716.
16. Hyde Ch., Peters J., Bondi M., et al. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. Age and Ageing 2013;42, 14-20.
17. Feldman H. H., Lane R. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2007;78, 1056-1063.
18. Mowla A., Mosavinasab M., Haghshenas H., Haghighi A. B. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. J. Clin. Psychopharmacol. 2007;27, 484-487.
19. Winblad B., Cummings J., Andreasen N., et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease: rivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry 2007;22, 456-467.
20. Van Dyck C. H., Tariot P. N., Meyers B., Malca Resnick E. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2007;21, 136-143.
21. Effectiveness and cost-effectiveness of acetylcholinesterase inhibitors. Downloaded from http://ageing.oxfordjournals.org/by guest on November 17, 2014 patients with moderate-to-severe Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2007;21, 136-143.
22. Gaugler J., David R. L., Haley W. E., Mittelman M. Can counselling and support reduce Alzheimer's caregivers' burden and depressive symptoms during the transition to institutionalization? Results from the NYU caregiver intervention study. J. Am. Geriatr. Soc. 2008;56(3), 421-428.
23. Sansoni J., Vellone E., Piras G. Anxiety and depression in community-dwelling, Italian Alzheimer's disease caregivers. Int. J. Nurs. Pract. 2004;10(2), 93-100.
24. Sansoni J., Anderson K. H., Varona L. M., Varela G. Caregivers of Alzheimer's patients and factors influencing institutionalization of loved ones: some considerations on existing literature. Ann. Ig. 2013;25, 235-246.
25. Blom M. M., Bosmans J. E., Cuijpers P., Zarit S. H., Pot A. M. Effectiveness and cost-effectiveness of an internet intervention for family caregivers of people with dementia: Design of a randomized controlled trial. BMC Psychiatry 2013;13(17), 1-7.
26. Borghi A. C., De Castro V. C., Marcon S. S., Carreira L. Overload of families taking care of elderly people with Alzheimer's disease: A comparative study. Rev. Latino-Am. Enfermagern 2013;21(4), 876-883.
27. Diel L., Forster L. M. K., Kochhann R., Chaves M. L. F. Sociodemographic profile and level of burden of dementia patients' caregivers who participate in a support group. Dement. Neuropsychol. 2010;4(3), 232-237.
28. Van Durme T., Macq J., Jeanmart C., Gobert M. Tools for measuring the impact of informal caregiving of the elderly: A literature review. Int. J. Nurs. Stud. 2011;49(4), 490-504.
29. Nylor M., et al. Advancing Alzheimer's diagnosis, treatment and care: Recommendations from the War Invitational Summit. Alzheimers Dement. 2012;8(5), 445-452.
30. Ivinson A. J., Lane R., May P. C., Hosford D. A., Carrillo M. C., Siemers E. R. Partnership between academia and insudtry for drug discovery in Alzheimer's disease. Alzheimer's & Dementia 2008;4, 80-88.
31. Socott, T. J., O'Connor, A. C., Link, A. N., & Beaulieu, T. J. Economic analysis of opportunities to accelerate Alzheimer's disease research and development. Ann. Y. Y. Acad. Sci. 2014;1313, 17-34.
32. Paul S. M., Mytelka D. S., Dunwiddie C. T., Persinger C. C., Munos B. H., Lindborg S. R., Schacht A. L. How to improve R & D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010;9, 203-214.
33. Karran E. Alzheimer's research U. K.: defeating dementia through research. Stem Cells Translational Medicine 2012;1, 449-450.
34. Cummings J. L., Morstorf T., Zhong K. Alzeheimer's disease drug-development pipeline: Few candidates, frequent failures. Alzeheimer's Research & Therapy 2014;6(37), 1-7.
35. Schneider L. S., et al. Clinical trials and late-stage drug development for Alzeheimer's disease: An appraisal from 1984 to 2014. Journal of Internal Medicine 2014;275, 251-283.
36. Zemek F., et al. Outcomes of Alzeheimer's disease therapy with acetylcholinesterose inhibitors and memantine. Expert Opin. Drug Saf. 2014;13(6), 759-776.
37. Korabecny J., et al. Pharmacotherapy of Alzeheimer's disease: Current state and future perspectives. Frontiers in Drug Design and Discovery 2014;6, 702-738.
38. Matl O., Holmerová I., Matlová M. Zpráva o stavu demence 2014. Downloaded from http://www.alzheimer.cz/alzheimerovachoroba-v-cr/zverejnena-zprava-o-stavu-demence-2014